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A B S T R A C T
The eighth annual conference of “Innovative therapy, monoclonal antibodies, and beyond” was held in Milan
on Jan. 26, 2018, and hosted by Fondazione IRCCS–Istituto Nazionale dei Tumori (Fondazione IRCCS INT).
The conference was divided into two main scientific sessions, of i) pre-clinical assays and novel biotargets,
and ii) clinical translation, as well as a third session of presentations from young investigators, which focused
on recent achievements within Fondazione IRCCS INT on immunotherapy and targeted therapies.
Presentations in the first session addressed the issue of cancer immunotherapy activity with respect to tumor
heterogeneity, with key topics addressing: 1) tumor heterogeneity and targeted therapy, with the definition
of the evolutionary Index as an indicator of tumor heterogeneity in both space and time; 2) the analysis of
cancer evolution, with the introduction of the TRACERx Consortium—a multi-million pound UK research
project focused on non-small cell lung cancer (NSCLC); 3) the use of anti-estrogen agents to boost immune
recognition of breast cancer cells; and 4) the high degree of functional plasticity within the NK cell repertoire,
including the expansion of adaptive NK cells following viral challenges. The second session addressed: 1) the
effectiveness of radiotherapy to enhance the proportion of patients responsive to immune-checkpoint
blockers (ICBs); 2) the use of MDSC scores in selecting melanoma patients with high probability to be re-
sponsive to ICBs; and 3) the relevance of the gut microbiome as a predictive factor, and the potential of its
perturbation in increasing the immune response rate to ICBs. Overall, a picture emerged of tumor hetero-
geneity as the main limitation that impairs the effectiveness of anti-cancer therapies. Thus, the choice of a
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specific therapy based on reproducible and selective predictive biomarkers is an urgent unmet clinical need
that should be addressed in order to increase the proportion of long-term responding patients and to improve
the sustainability of novel drugs.
1. Introduction
National and international clinical and pre-clinical experts in im-
muno-oncology and cancer cell signaling gathered at the eighth annual
edition of “Innovative therapy, monoclonal antibodies, and beyond,”
organized by Fondazione IRCCS Istituto Nazionale dei Tumori
(Fondazione IRCCS INT) in Milan, Italy, on Jan. 26, 2018. State-of-the
art approaches and the current and future challenges in the fields of
immune-, targeted- and radio-therapies were presented. Specifically,
Session I comprised the following topics: 1) tumor heterogeneity and
targeted therapy; 2) repurposing anti-estrogens to boost drug immune-
mediated activity in breast cancer; 3) functional diversification of
human NK cells: implications for cell-based cancer immunotherapy; 4)
neoantigen landscape and its impact on immune checkpoint inhibition;
and 5) links between the gut microbiome and tumor immune surveil-
lance. Session II dealt with: 1) MDSC scores; 2) radiotherapy in the era
of ICI-based immunotherapy; and 3) Immune checkpoint inhibitors as
new combinations in melanoma. Finally, the conference was closed
with presentations in Session III from selected abstracts of junior re-
searchers, on the topics of: 1) improvement of HER-2–positive gastric
cancer patient selection for trastuzumab treatment; 2) the impact of
cycling a fasting mimicking diet (FMD) on cancer patient metabolism;
3) upregulation of PD-L1 expression in triple-negative breast cancer
stem cells as a potential shield against immune-mediated tumor rejec-
tion; and 4) the neutrophil extracellular traps and alteration of T-cell
homeostasis in the bone marrow leukemic niche. Overall, clinicians and
basic and translational scientists provided the audience with a broad
overview of the most recent achievements that have been put forward
as ways of best exploiting personalized anti-cancer treatment.
2. Session I: preclinical assays and novel biotargets
2.1. Tumor heterogeneity and targeted therapy
In Session I, Filippo De Braud (Fondazione IRCCS INT and
Department of Oncology and Hemato-oncology, University of Milan)
addressed the key topic of tumor heterogeneity as the crucial “cause”
for anti-tumor therapies resistance and failure. In particular, and ac-
cording to the extensive literature on this subject, the speaker dis-
tinguished two types of cancer-related heterogeneity as inter- and intra-
tumor. As both of these types are associated with cancer stemness and
clonal evolution theories, they are characterized by the possibility of
dynamically changing over time, which delineates an evolutionary
index (Evo Index). The Evo-index [1] is a combination of two funda-
mental tumor-specific components: the diversity (D) or intra-tumoral
heterogeneity of the neoplasm, and the measure in which it changes
over time. Evo-index quantifies heterogeneity in both space and time,
and it is mostly responsible for the resistance to different agents that
result in the failures of a therapeutic regimen and of valid identification
by predictive biomarkers.
Solid tumors are characterized by the sequential accumulation of
molecular alterations that are driven by a selective pressure and sub-
sequent clonal evolution; these account for a high spatial and temporal
heterogeneity [2] and are one of many contributing factors for re-
sistance against targeted therapies [3]. A paradigm of genomic het-
erogeneity involvement in resistance to targeted therapies is re-
presented by the acquired resistance to anti-EGFR monoclonal
antibodies (mAbs) in patients with metastatic colorectal cancer
(mCRC). Unlike the case of anti-EGFR–acquired resistance in NSCLCs
[4], the high intralesional and interlesional tumor molecular
heterogeneity that characterize secondary resistance to panitumumab
or cetuximab in mCRC have prevented us until now from efficiently
targeting all resistant clones with a single targeted agent [5]. PD-L1
expression is actually the most widely used biomarker-guided immune
checkpoint–targeted therapy, but it is characterized by high levels of
intralesional, interlesional, and temporal heterogeneity [6,7]. For ex-
ample, in patients with muscle-invasive, platinum-resistant bladder
cancer, platinum-based chemotherapy causes (as a resistance me-
chanism) molecular alterations in genes regulating cell cycle and up-
regulation of PD-L1 [8]. Of note, this observation suggests that, if PD-L1
expression is used to select bladder cancer patients for treatment with
PD-1/PD-L1 inhibitors after platinum failure, this temporal hetero-
geneity should be taken into account, and pre-chemotherapy tumor
samples should not be tested for PD-L1. Moreover, immune checkpoint
inhibitors efficacy can be impaired by intratumoral and spatial het-
erogeneity of inflammatory infiltrate [9,10] as well as of somatic mu-
tational profiles [11] and by HLA loss of heterozygosity [12]. Tumor
heterogeneity is also one of the main reasons why the novel break-
through immunotherapy strategy, of the chimeric antigen receptor
(CAR) T-cell adoptive therapy, currently lacks efficacy in solid tumors
as compared to hematological malignancies [13]. In fact, tumor-asso-
ciated antigens (TAAs) that can be targeted to solid tumors are subject
to a more pronounced intra- and interlesional heterogeneity with re-
spect to tumor-associated antigens, which are usually targeted to he-
matological malignancies [13]. A typical case is represented by the high
intra-tumor heterogeneity of NY-ESO-1 expression, one of the most
immunogenic TAAs in solid tumors [14]. Lastly, another context linked
to intra-tumor heterogeneity is represented by metabolic reprogram-
ming, an intriguing target for anti-cancer innovative therapies as its
dysregulation sustains survival and rapid proliferation, immune-eva-
sion, and resistance to targeted agents [15–17]. Taken together, these
observations highlight the need of a deeper understanding of these
phenomena, in order to improve clinical outcomes of cancer patients.
2.2. Repurposing anti-estrogens to boost drug immune-mediated activity in
breast cancer
Elda Tagliabue (Fondazione IRCCS INT, Milan) provided the audi-
ence with the latest updates about the role of immune system in breast
cancer. While breast carcinoma (BC) is not considered an immunogenic
tumor, different clinical studies showed that the presence of tumor in-
filtrating lymphocytes play a prognostic and predictive role, and in
particular in estrogen receptor (ER)-negative (ER–) tumors. Higher le-
vels of TILs were found to be significantly associated with outcome
disease in both TNBC and HER2-positive BC.
The presence of high levels of immune infiltrating cells may depends
on cancer-specific mutations even though, as compared to other solid
tumors, BCs have a low mutation rate with considerable variation be-
tween disease molecular subtypes. Aside from mutant peptides, the
presentation of damaged intracellular proteins can generate tumor an-
tigens. Tumor cell death, either spontaneous or induced by therapy, can
lead to the release of immunogenic signals in the surrounding micro-
environment. Chemotherapy and radiotherapy are not the only treat-
ments that interact with tumor immune microenvironment. Indeed,
part of the therapeutic activity of antibodies targeting tumor–cell sur-
face antigens, such as the anti-HER2 mAb trastuzumab, is mediated
through immunological mechanisms by sensing local immune cells that,
in turn, activate an antigen-specific antitumor immune response [18].
Inflammatory mediators can be produced by activation of various types
of oncogenes by mutation, chromosomal rearrangement, or
without prior sensitization [19]. Recent breakthroughs have revealed a
high degree of functional plasticity within the NK cell repertoire, in-
cluding the expansion of adaptive (memory) NK cells following viral
challenges [20]. Karl-Johan Malmberg (University of Oslo, Norway,
and Karolinska Institute, Stockholm Sweden) described their recent
efforts to decipher fundamental mechanisms concerning the differ-
entiation, plasticity, and functional regulation of diverse human NK cell
subsets. Their ultimate goal is to harness these insights into the design
of novel, targeted NK cell–based therapies against cancer.
Discrimination of self from non-self through the continuous selec-
tion of effector specificity is the backbone of effective immunity. For NK
cells, this specificity is achieved by unique combination of variable
germ-line receptors, able to recognize self-MHC antigens [21]. In-
hibitory interaction between NK cell receptors and self-ligands is the
key determinant in functional potentiation of pre-primed effector re-
sponses, a process termed NK cell education [22]. The calibration of
effector potential to self-MHC allows for the rapid sensing of dis-
continuity in the level of MHC expression during infection, cellular
stress or tumor transformation, whilst operating within a framework of
overall tolerance to normal tissues. However, the cellular mechanism
behind NK cell education remains poorly understood. By using high-
resolution flow cytometry combined with confocal imaging and im-
muno-electron microscopy, Malmberg and his team discovered that
educated NK cells display a unique accumulation of dense-core secre-
tory lysosomes with high granzyme B content [23]. RNA-seq of sorted
NK cell subsets showed that this discrete morphological phenotype
persists in resting NK cells independently of transcriptional programs
that regulate metabolism and lysosomal biogenesis. Further, pharma-
cological inhibition and gene-silencing experiments revealed a role for
the lysosome-specific Ca2+-channel TRPML1 and its upstream activator
PIKfyve in the modulation of the secretory lysosomes and the global
functional responsiveness of human NK cells. These results support a
model in which unopposed chronic signaling through activating re-
ceptors disarms NK cells through TRPML1-mediated modulation of the
acidic Ca2+ stores. This in turn is reflected in differences in the func-
tional responsiveness between self and non-self KIR+ NK cells, pro-
viding important mechanistic insights into the connection between
Fig. 1. HER2 oncogene induces the tumor production of CCL2 through PI3K-NF-kB signaling pathway. CCL2 recruits macrophages improving trastuzumab-dependent
phagocytosis (ADCP). Estrogen (E2)-estrogen receptor (ER) complex inhibits NF-kB activity abrogating CCL2 production, macrophages recruitment and ADCP.
amplification, a s well a s t he i nactivation o f t umor-su ppressor genes, 
thereby generating an inflammatory microenvironment. In this context, 
the team of Dr. Tagliabu e recently determined that stimu lation of 
HER2 + BC cells with anti-HER receptor ligands as EGF/HRG leads to 
the production of CCL2, which is a chemokine involved in monocyte 
recruitment via the PI3K/NF-kB signaling axis (Fig. 1). The concept is 
that the activated HER2 oncoprotein regu lates recru itment and acti-
vation of pro-trastu zu mab tu mor-infiltrating i mmu ne c ells through 
production of CCL2, which is supported by evidence that trastuzumab 
efficacy relies on CCL2 levels and monocytes present in the tumor mi-
croenvironment. A major role in the resistance to trastuzumab-based 
treatments is played by the expression and activity levels of ER in tu-
mors. ER is a ligand-dependent transcription factor that regulates the 
expression of a variety of genes, both by binding to specific response 
elements located in their promoters and by modulating the function of 
other transcription factors, such as NF-kB.
In line with the ER repressive activity of NF-κB, Dr. Tagliabue´s 
group found that ER negatively controls the HER2-driven pro-trastu-
zumab tumor microenvironment, and that fu lvestrant, a selective ER 
down-regulator, promotes increased NF-kB transcriptional activity and 
enhanced CCL2 expression. Therefore, ER inhibition may represent an 
avenu e to increase the pro-trastu zu mab tu mor immu ne infiltration 
driven by HER2. Finally, ERs also regulate pathways in the innate and 
adaptive immu ne cells, mainly by enhancing their intrinsic im-
munosuppressive activity.
Overall, blocking estrogen signaling in patients with BC may re-
present a promising method of boosting the immune cell contribution to 
improve anticancer therapies, especially in triple-positive BCs. However, 
further studies considering the type of endocrine therapy and the host 
estrogen levels are needed to determine how to combine ER blocks with 
anti-tumor treatments (including emerging immunotherapies).
2.3. Functional diversification of human NK cells: implication for cell-based 
cancer immunotherapies
Representing key cellular components of the innate immune system, 
natural killer (NK) cells display an intrinsic capacity to kill tumor cells
• To define the relationship between intra-tumor heterogeneity and
clinical outcome following surgery and adjuvant therapy (including
relationships between intra-tumor heterogeneity, clinical disease
stage and histological subtypes of NSCLC);
• To establish the impact of adjuvant platinum-containing regimens
upon intra-tumor heterogeneity in relapsed disease compared to
primary resected tumor.
Intra-tumor heterogeneity is increasingly recognized as a major
hurdle to achieve improvements in therapeutic outcome and biomarker
validation. Intra-tumor genetic diversity provides a substrate for tumor
adaptation and evolution. However, the evolutionary genomic land-
scape of NSCLC and its changes throughout the disease course have not
been studied in detail. The key secondary objects could be identified in
the development and validation of intra-tumor heterogeneity (ITH)
ratio index as a prognostic and predictive biomarker in relation to
disease-free survival and overall survival. This would complete a pic-
ture of NSCLC evolutionary dynamics and define drivers of genomic
instability, metastatic progression, and drug resistance by identifying
and tracking the dynamics of somatic mutational heterogeneity, and
chromosomal structural and numerical instability present in the pri-
mary tumor and at metastatic sites. The discovery of novel targets to
improve outcome is a key element in any comprehensive program of
lung cancer research. Whilst emerging evidence suggests that intra-
tumor heterogeneity may significantly limit the anti-tumor activity of
targeted therapeutics, its overall effect on the anti-cancer immune re-
sponse may prove tractable, as high levels of intra-tumoral mutational
diversity may generate neo-antigens perceived by the immune system
as non-self, thus providing relevant targets for immune-based therapies.
TRACERx will provide the future resource to define how intra-tumor
heterogeneity impacts upon cancer immunity throughout tumor evo-
lution and therapy. Such studies will help to define how the clinical
evaluation of intra-tumor heterogeneity will guide patient stratification
as well as the development of combinatorial therapies that incorporate
conventional, targeted and immune-based therapeutics. This landmark
study will bring together more than 80 lung cancer researchers in the
UK, including oncologists, pathologists, laboratory researchers, and
technicians, who are based in hospitals, universities, and research in-
stitutes.
2.5. Links between the gut microbiome and tumor immune surveillance
Laurence Zitvogel (University of Paris Medical School) presented
a keynote lecture, in which presented her team’s latest studies re-
lating to the role of gut microbiome composition in cancer im-
munotherapy activities [25,26]. Immune checkpoint inhibitors (ICI)
have now emerged as an innovative strategy for treating distinct
cancers. However, most patients treated with ICIs do not benefit from
immunotherapy. One of the putative mechanisms responsible for
resistance to ICIs is the heterogeneity of gut microbiota. Indeed, the
intestine represents the largest compartment of the immune system,
and the recent advances in both sequencing technologies and cul-
turomics have allowed microbiota to not only be characterized but
also be defined with respect to their roles in human health and dis-
ease [27]. The existence of commensal bacteria represents a protec-
tion against pathogens and plays a pivotal role in some diseases, such
as inflammatory bowel diseases, type 1 diabetes mellitus, metabolic
and cardiovascular disorders, and cancer [28–31]. The influence on
host immune systems may affect the efficacy of some agents; the
mechanisms of action are currently under investigation. Notably,
Prof. Zitvogel’s team recently revealed that certain constituents of
gut microbiota may influence the efficacy and toxicity of cancer
immunotherapy, and specifically those directed to the CTLA-4
checkpoint blockade [25]. Further, Zitvogel and collaborators de-
monstrated that the therapeutic efficacy of anti–CTLA-4 antibodies is
lost in mice treated with broad-spectrum antibiotics and, im-
portantly, in mice kept under germ-free conditions that received
fecal microbiome transplantation from non-responding human in-
dividuals [32–34). At the clinical level, it was observed that “gen-
erally” broad-spectrum antibiotic intake reduced survival of ad-
vanced cancer patients treated with PD-1/PD-L1 inhibitors. This
effect was observed also in sarcomas, melanomas, and colon cancers.
Of note, these findings will likely introduce a new direction in im-
muno-oncology research focused on testing adjunctive antibiotics
that may facilitate the effectiveness of cancer immunotherapy by
ensuring optimal microbiota composition. In each case, therapeutic
efficacy was impaired when the gut microbiota was absent or ma-
nipulated and may differ for each treatment setting. Zitvogel detailed
some of the major factors useful for deciphering the clinical im-
portance of gut microbiome:
1 Fecal transplantation into mice and fecal composition, which in-
fluences the anti-tumor efficacy of anti-PD-1 Abs in mice;
2 Metagenomics analysis of the microbiota, in particular to determine
the percentage of bacteria in the microbiota, which allows different
levels of response to therapy;
3 The culturomics of fresh stool from patients, which could become a
predictor of the treatment outcome.
Critically, the close interactions that exist between cancer, im-
munity, and microbiota could now be addressed using novel and es-
tablished technologies such as metagenomics, metatranscriptomics,
culturomics, and metabolomics. Finally, directed perturbation of the
gut microbiome could provide new useful information for the quest of
increasing the response rate to ICI therapy.
su rface receptor inpu t and the functional phenotype of educated NK 
cells. This new discovery suggests that NK cells process and integrate 
receptor inpu t du ring education into a form of “molecu lar memory” 
stored in dense-core secretory lysosomes. Finally, Malmberg discussed 
the implications of these findings and the current efforts to selectively 
expand edu cated, highly fu nctional NK cells for cell therapy against 
acute myeloid leukemia and myelodysplastic syndrome.
2.4. Neoantigen landscape and its impact on immune checkpoint inhibition
Nicholas McGranahan (Cancer Research UK Lung Cancer Centre of 
Excellence, London Cancer Institute) presented research into intra-
tumor heterogeneity across cancer types, and introduced the audience 
to the TRACERx (TRAcking Cancer Evolution through therapy [Rx]) 
Consortium. The TRACERx study started in 2014 and will take place 
over nine years, with the goals of transforming our understanding of 
non-small cell lung cancer (NSCLC) and taking a practical step to-
wards an era of precision medicine. The study aims to uncover me-
chanisms of cancer evolution by analyzing the intra-tumor hetero-
geneity in lung tumors from approximately 850 patients and then 
tracking their evolutionary trajectories from diagnosis through re-
lapse. At £14 million, TRACERx represents the biggest single invest-
ment in lung cancer research by Cancer Research UK, and the start of a 
strategic UK-wide focus on the disease, aimed at making real progress 
for patients.
Led by Charles Swanton (Francis Crick Institute, UK) [24], the study 
will bring together a network of experts from different disciplines to 
facilitate integration of clinical and genomic data and to identify pa-
tients who cou ld benefit f rom t rials o f novel t argeted t reatments. In 
addition, the stu dy will u se a whole su ite of cu tting-edge analytical 
techniques, giving unprecedented insight into the genomic landscape of 
primary and metastatic tumors.
In the fu ture, TRACERx will enable us to define how intra-tumor 
heterogeneity impacts cancer immu nity throu ghou t tu mor evolution 
and therapy. The primary objects of the consortium are:
blood, implying that a systemic phenomenon plays a key role in disease
progression [43]. Furthermore, their presence in peripheral circulation
makes them an ideal source of prognostic and predictive biomarkers. In
a population of 122 advanced melanoma patients undergoing therapy
with immune checkpoint inhibitors (ICI) or a BRAF/MEK inhibitor
(tyrosine kinase inhibitors, TKI), Licia Rivoltini (Fondazione IRCCS INT,
Milan) reported that the frequency above cut-offs of defined im-
munosuppressive monocytic and granulocytic cell subsets (globally
identified in a myeloid index score, MIS) in baseline blood predicts poor
clinical outcome and rapid progression during therapy, independent of
the type of treatment. Patients with MIS=0 had a median OS of about
24 months, while patients with MIS > 0 had a severely reduced
median OS, of only 8 to 2 months; this was confirmed in an independent
validation case-set. Applying an in vitro model of myeloid cell con-
ditioning by melanoma extracellular vesicles, a specific panel of
miRNAs responsible for the generation of myeloid immunosuppressive
cells (MDSC) could be identified. This MDSC-miR panel (including miRs
known to regulate myeloid cell function, such as miR146a, miR125b,
and miR155) was found to be amplified in circulating myeloid cells of
melanoma patients with respect to healthy individuals, and in meta-
static melanoma lesions in association with myeloid cell infiltrate. Most
importantly, high levels of these miRs in baseline plasma of advanced
melanoma patients predict resistance to therapy with ICI but not with
TKI. This indicates that defined MDSC functional properties have an
active role in restraining T-cell function upon ICI-mediated activation,
making them good prognostic biomarkers and predictive factors of re-
sistance to therapy. Altogether, the data indicate that systemic, cancer-
related myeloid conditioning can profoundly affect responses to treat-
ment in patients with melanoma; thus, they should be included in the
evaluations required for screening patients and directing therapeutic
choices.
3.3. Immune checkpoint inhibitors: new combinations in melanoma
Immune checkpoint inhibitors comprise the standard care in the
treatment of several different tumors, but unfortunately, the response
rates are not optimal for melanomas, with a maximum rate of 44%
response indicating that most patients are unresponsive to these treat-
ments (innate resistance). Further, as addressed by Michele Del Vecchio
(Fondazione IRCCS INT, Milan), one-third of patients relapse after an
initial response (due to adaptive resistance), which suggests the ex-
istence of multiple, non-redundant mechanisms of immunosuppression
within the tumor microenvironment. Therefore, a combination strategy
for treatment of these tumor would be desirable, in order to hit si-
multaneously more than one mechanism responsible for tumor immune
escape. Del Vecchio’s team has now determined that a combination of
nivolumab plus ipilimumab obtained an overall response rate (ORR) of
up to 58.3%, with 19.4% of patients obtaining a complete response
(note that the median duration of response for these patients cannot be
determined, as they have not yet relapsed). A major drawback of this
treatment is the observation that it is associated grade 3/4 treatment-
related adverse events (AE) in 58.8% of the cases; treatment was dis-
continued due to AEs (of any grade) in 39.3% of cases, even though
67% of these patients (for whom treatment was discontinued) are still
alive at three years post treatment [44].
A series of immune-modulating activities underlies the combination
of targeted therapies, such as the TKIs BRAF and MEK inhibitors, with
checkpoint blocker-based immunotherapy. In particular, BRAF in-
hibitors are able to oppose the constitutive internalization and en-
dolysosomal sequestration of MHC class I molecules associated with
activated MAPK signaling pathway, thereby: i) increasing the expres-
sion of melanocytic antigens and the tumor infiltration of CD8+T
cells; to reduce immunosuppressive cytokines (IL-6, IL-10, TGF-β); ii)
enhancing the expression of immune inhibitory markers (e.g. PDL-1);
and iii) decreasing the recruitment of immunosuppressive cells
(CCR2+Tregs, MDSCs) inside the tumor microenvironment [45,46].
3. Session II: clinical translation
3.1. Radiotherapy in the era of ICI-based immunotherapy
Davide Franceschini (Hu manitas Research Institu te, Milan) re-
viewed the role of radiotherapy (RT) as a therapeutic tool for increasing 
the proportion of patients who will benefit from ICBs. RT presents an 
ideal tool, as it is easily accessible, deliverable to virtually any patient 
and any site, cost-effective, and already part of the standard of care for 
almost every cancer regime. More importantly, RT is immunogenic, as 
it provokes the release of new antigens in numerous ways, including: 1) 
via RT-killed tumor cells; 2) by the destruction of the tumor-supporting 
stroma; 3) by an increased expression of pro-inflammatory cytokines. 
Usually referred as “immunogenic modulation”, all these radiation-in-
duced molecular alterations in the biology of the cancer cell make the 
tumor more amenable to cytotoxic Tlymphocyte–mediated destruction 
[35]. This interaction has been proven in various pre-clinical experi-
ences [36,37] and has its clinical counterpart in the so-called “abscopal 
effect”. This term is used to identify a response of metastatic deposits 
that had not been directly irradiated, after the patient had received RT 
in another site. This effect i s m ediated b y t he i mmu ne s ystem re-
activated by the X-rays. The main limitation is that an abscopal effect is 
very rarely observed in the clinical practice when RT is u sed alone. 
Therefore, combining RT with immunotherapy (IT) could not only in-
crease the efficacy of the drugs, but also increase the occurrence of an 
abscopal effect c orrelated w ith a  b etter p rognosis f or p atients [38]. 
Despite the great amount of preclinical studies exploring a combined 
RT-IT treatment, clinical data are rare and are mostly represented by 
retrospective experiences, mainly from melanoma patients. Altogether, 
these stu dies support a possible synergism between RT and IT, with 
su rvival improvements reported in most of these papers [39]. In-
formation abou t safety of the combinations also emerges from these 
data; importantly, no significant increases in the expected toxicity have 
been observed.
Stu dies focu sing on the possible combination of RT and IT have 
been conducted and are ongoing for patients with lung cancer as well. A 
subgroup analysis of the phase I study of pembrolizumab IT showed 
that patients with lung cancer who had also been treated with RT before 
the first administration of pembrolizumab had better progression-free 
su rvival (PFS) (of 4.4 compared to 2.1 months) and overall survival 
(OS) (of 10.7 compared to 5.3 months) than patients treated with 
pembrolizumab only. More recently, in the Pacific phase III trial, locally 
advanced NSCLC patients were treated with definitive chemo-radio-
therapy for one year and thereafter with either durvalumab or placebo. 
Patients treated with durvalumab IT had a significantly better PFS than 
those treated with placebo (of 16.8 compared to 5.6 months) [40]. 
These promising resu lts requ ire fu rther stu dies to better detail the 
mechanism(s) underlying their benefits and to address numerous un-
answered qu estions. Aspects that remain u nclear and shou ld be ad-
dressed are: i) the ideal sequence of the combined RT-IT for maximizing 
the synergistic advantage; ii) the most suitable RT dosage and fractio-
nation for stimu lating the immu ne system; and iii) how to identify 
patients who can benefit f rom t his c ombination t reatment. Ongoing 
trials will hopefully answer these and other outstanding questions, so 
that the combination of RT-IT can be used to improve patient survival 
and prognosis.
3.2. MDSC score
It is well established that cancer immunity includes a complex and 
interconnected immunosuppressive processes that favor tumor growth 
by restraining adaptive immunity. Myeloid cells are one of the major 
mediators of this immunosuppression due to their high plasticity, their 
ability to undergo reprogramming in the periphery, and the profound 
conditioning effect that tumor exerts on myelopoieis [41,42]. In cancer 
patients, myeloid cell dysfunctions are detectable in lymph nodes and
Using the triple combination (anti-PD-1/PD-L1 + BRAF
inhibitor+MEK inhibitor) has a main objective of putting together the
positive features of the two single treatments: rapid activity for a large
number of patients (from the targeted therapy), and prolonged response
duration (from the immunotherapy). Clinical trials are ongoing to de-
termine whether such approach is better than the double-combination,
and whether it has an acceptable toxicity profile [47,48]. Finally, an-
other method that is being tested is the combination of antagonist mAbs
directed to different co-inhibitory receptors (e.g., anti-PD-1 + anti-
LAG-3).
The activation of the adenosinergic pathway inside the hypoxic
tumor cells seems to contribute significantly to tumor growth and
metastatization through effects on both tumor cells and stroma [49].
Early phase I clinical trials are ongoing for several different tumor types
(such as the one in which the Del Vecchio team at the Fondazione
IRCCS INT is involved with), even in combination with anti-PD-1 mAbs.
Other clinical trials are ongoing to confirm the so called “abscopal ef-
fect”, that is, the activity of radiation therapy also in distant tumor sites
different from the specific lesion irradiated, following the immunogenic
cell death and the consequent cross-priming with the activation of the
immune system [50].
Crucial issues that now should be addressed in the near future are
finding an optimal combination of immune checkpoint inhibitors with
vaccinations, and identifying potential biomarkers predictive of re-
sponse/resistance to immunotherapy.
4. Session III: selected oral abstracts
4.1. Survival probabilities of gastric cancer patients
Gastric cancer (GC) is the second leading cause of cancer-related
deaths worldwide, with unsatisfactory long-term survival following
standard treatments [51]. HER2 overexpression/amplification is found
in less than 20% of cases, but frequent heterogeneity of HER2 as a
"leading" oncogenic driver poses fundamental clinical challenges. In
metastatic GC (mGC), all major guidelines currently recommend HER2
testing to guide patient selection for trastuzumab treatment [52], be-
cause the addition of trastuzumab to double chemotherapy was shown
to significantly improve all endpoints (overall response rate, PFS, and
OS) in the pivotal ToGA trial [53]. However, the relatively un-
satisfactory median PFS of 6.7 months in the trastuzumab arm, and the
overlapping of PFS curve tails, clearly indicate the relevance on survival
of primary and acquired resistance [54]. Additionally, subsequent trials
with anti-HER treatments for mGC in different settings did not meet the
expectations based on the positive data in HER2-positive breast cancer.
In particular, the Jacob trial failed to demonstrate a statistically sig-
nificant improvement in OS with the addition of pertuzumab to tras-
tuzumab and chemotherapy in the first line setting, even if a 3.3-month
increase in median OS was reported [55]. Therefore, there remains an
unmet need for (a) an optimal clinical definition of primary and ac-
quired resistance to anti-HER treatment; and (b) predictive biomarkers
able to improve the design and the statistical power of future pro-
spective studies.
Encouraging results for patients with HER2-positive gastric cancer
(GC) whose long-term survival is still unsatisfactory following standard
treatments were presented by Filippo Pietrantonio (Fondazione IRCCS
INT and University of Milan). Pietrantonio and colleagues recently
provided the first prospective demonstration of the clinical usefulness
of candidate genomic alterations (the AMNESIA panel including EGFR/
MET/KRAS/PI3K mutations and EGFR/MET/KRAS amplifications)
[56]. The study design is summarized in Fig. 2.
Criteria for trastuzumab resistance were: progressive disease at the
first CT scan; reassessment during trastuzumab plus chemotherapy; and
stable disease lasting ≤ 4 months after treatment start. Criteria for
trastuzumab sensitivity were initial partial/complete response and
subsequently progressive disease at least 3 months after the last
chemotherapy dose. The AMNESIA panel was able to predict primary
resistance to trastuzumab in 55% of patients with HER2-positive mGC
included in this case-control study (Fig. 3).
No patient included in the sensitive cohort (control) had the al-
terations present in the AMNESIA panel. Data demonstrated that pa-
tients with tumors bearing no candidate alterations had a significantly
longer median PFS (5.2 compared to 2.6 months; HR, 0.34; 95% con-
fidence interval, 0.07–0.48; p 0.001) and OS (16.1 compared to 7.6
months; HR, 0.38; 95% confidence interval, 0.09–0.75; p 0.015). The
strength of the AMNESIA panel relies on: (a) the simultaneous assess-
ment of multiple resistance mechanisms with an individual low fre-
quency, but reaching 55% when combined together as "AMNESIA
panel." This approach may provide a greater chance of validating
genomic signatures as opposed to attempts of investigating just one
biomarker at a time; (b) clinical selection of adequate patients, by
adopting restrictive criteria for defining primary resistance versus clear
sensitivity based on the combined assessment of RECIST response and
time to progression, in order to overcome the challenge represented by
the potential activity of chemotherapy; (c) the case-control study design
based on a predefined statistical hypothesis. Thus, using the results of
the AMNESIA panel provides a good strategy for improving patient
selection for future clinical trials with anti-HER treatments; however,
the lack of an untreated group in this study makes it necessary to fur-
ther validate the panel before using it in prospective trials.
4.2. Impact of cyclic fasting mimicking diet (FMD) on cancer patient
metabolism
Preclinical studies performed in recent years have suggested that
reducing the concentration of glucose and growth factors, such as in-
sulin and insulin-like growth factor 1 (IGF-1), in cancer cell growth
media sensitizes tumor cells to the cytotoxic effects of several che-
motherapeutic compounds, such as platinum salts, alkylating agents
and doxorubicin, as well as to different molecular targeted therapies
[57]. Many metabolic effects of in vitro starvation can be recapitulated
in vivo by cyclic fasting, which reduces plasma glucose and amino acids,
as well as serum growth factors [15]. In preclinical in vivo murine
models, cyclic fasting concomitant with chemotherapy administration
improves the anticancer effects of cytotoxic treatments, while pro-
tecting normal tissues from chemotherapy-induced toxicities [57]. So
far, only few trials have assessed the safety of complete fasting for 1–3
consecutive days during chemotherapy administration. According to
these studies, fasting was feasible and was associated with reduced
chemotherapy-induced hematologic toxicities, including thrombocyto-
penia, erythrocytopenia, and DNA damage to circulating leukocytes
[59,60]. However, the specific impact of fasting on human cancer
growth and on mechanisms affecting the response to antitumor treat-
ments is still unknown.
The main limitation related to complete fasting is its poor toler-
ability by most cancer patients, as demonstrated by poor accrual in
Fig. 2. Study flowchart.
Adapted from Pietrantonio F. et al., Clin Cancer Res. 2018 Mar
Fig. 3. Heatmap and predictive accuracy of AMNESIA panel.
Adapted from Pietrantonio F. et al., Clin Cancer Res. 2018 Mar
Fig. 4. DigesT trial (NCT NCT03454282) flowchart: patients with breast cancer or melanoma who are candidate to be treated with curative surgery will undergo one
5-day FMD cycle about 1 week before undergoing surgery.
immunotherapy or other biological treatments. In parallel with the
clinical trial, preclinical experiments in mouse models of breast cancer
and melanoma will evaluate the anticancer activity of the FMD, alone
or in combination with anti-PD1 monoclonal antibodies.
4.3. Triple-negative breast cancer stem cells up-regulate PD-L1 expression as
a potential shield against immune-mediated tumor rejection
TNBC is a molecular BC subgroup characterized by worse prognosis
and currently still orphan of specific therapeutic targets whose identi-
fication is an urgent medical need [63]. Recently, immune checkpoint
inhibitors, which block the PD1/PD-L1 axis, have been identified as
promising therapeutics capable of restoring the T-cell immune response
and achieving an effective tumor inhibition [64]. Promisingly, the ad-
ministration (in the NCT01375842 trial) of atezolizumab, a monoclonal
anti-PD-L1 antibody, induced 19% of ORR in metastatic TNBC [65];
nonetheless, the clinically objective responses fall short of making a
significant improvement. In this context, evidence underlined the im-
plication of cancer stem cells (CSC), a small but biologically relevant
tumor cell subset involved in tumor-initiation, progression, and me-
tastatization [66], as well as in evasion from anti-tumor immune attack
in the early phases of carcinogenesis [67]. In addition, the expression of
PD-L1 has recently been reported to be in the stem cell compartments of
some solid tumors; however, while no findings are yet available for
TNBC stem cells (TNBC-SCs).
Research presented by Lorenzo Castagnoli (Fondazione IRCCS INT,
Milan) is now focused on the analysis of PD-L1 expression in TNBC-SCs
to assess its role as potential immune-modulator of the anti-tumor im-
mune response. In-house profiled human TNBCs (n=158) that were
molecularly stratified for high levels of PD-L1 (PD-L1High) showed sig-
nificantly enriched expression of immune and cancer stemness path-
ways as compared with those with low PD-L1 expression (PD-L1Low). In
addition, the PD-L1High cases were significantly associated with a sig-
nature of a high stemness score (SSHigh). Functional bioassays strongly
suggested that PD-L1 up-regulation was orchestrated by activation of
the WNT signaling genes pathway. In keeping with these results,
Castagnoli and colleagues also detected, in five distinct TNBC cell lines,
a specific higher expression of PD-L1 in the ALDH-positive and
CD44High TNBCSC subsets as compared to their negative counterparts
(Fig. 5). Further, they observed that PD-L1-positive tumor cells had a
significantly higher mammosphere-forming efficiency as compared to
PD-L1-negative cells. Remarkably, human TNBC samples contained
tumor elements co-expressing PD-L1 with ALDH1A1 and/or CD44v6
cancer stemness biomarkers.
In addition, in vivo analysis of the tumor-forming ability of a high-
grade murine mammary tumor cell line, sorted according to PD-L1
Fig. 5. Representative IF analysis of co-localization of human canonical cancer stemness biomarkers (CD44v6 and ALDH1A1) and PD-L1 in TNBC specimens.
clinical trials that were started in the past decade. In recent years, the 
group of Valter Longo proposed a dietary regimen able to produce si-
milar biological effects a s c omplete f asting, w hile b eing potentially 
more tolerated by cancer patients [61]. This approach is known as 
“fasting-mimicking diet” (FMD) and consists in a cyclic, calorie-re-
stricted (400–800 Kcal/day), low-carbohydrate, low-protein diet to be 
administered cyclically [61]. In preclinical experiments, FMD inhibited 
in vivo tumor growth similarly to complete fasting, while synergizing 
with cytotoxic chemotherapy to activate antitumor immunity and to 
inhibit tumor growth [62]. In healthy volunteers, every-four week FMD 
was quite well-tolerated, and associated with reduced total and trunk 
fat, diastolic/systolic blood pressure, and reduced plasma IGF-1 levels 
[61].
Claudio Vernieri (Fondazione IRCCS INT, IFOM, and FIRC Institute 
of Molecular Oncology, Milan) and colleagues are now conducting the 
clinical trial NCT03340935, aimed at assessing the safety, feasibility 
and metabolic effects o f 5 -day FMD i n patients with d ifferent tumor 
types and stages, or 5-day FMD concomitant with different treatments. 
Patients who are shown to be highly motivated to fast du ring their 
standard anti-tumor treatments are considered for enrollment in the 
study. The same FMD scheme is prescribed to all patients, and the diet 
is repeated every 3 to 4 weeks, with an allowed maximum of 8 con-
secu tive FMD cycles. To date, 63 patients have been enrolled from 
Febru ary to November 2017. All patients u ndergo blood and urine 
sampling before the initiation and at the end of each FMD cycle to 
measure changes in the concentration of plasma glucose, triglyceride 
and cholesterol, serum insu lin, and IGF-1 and urine ketone bodies is 
measu red. Based on preliclinical evidence showing an impact of the 
FMD in activating antitumor immunity, a new study, namely the DigesT 
trial (NCT NCT03454282), will be started soon to assess the effects of 
one FMD cycle on patient peripheral blood immune profile. In parti-
cular, patients with breast cancer or melanoma who are candidate to be 
treated with curative surgery will undergo one 5-day FMD cycle about 1 
week before undergoing surgery. As shown in the Fig. 4, blood, urine 
and stool samples will be collected before and at the end of the FMD, as 
well as on the day of surgery and at one month after surgery, to eval-
uate the effect of the FMD on metabolic and immunological parameters 
(composition of PBMC popu lations, transcriptome and epigenetic 
modifications) as well as on the bacterial composition of the gut mi-
crobiota. Immunohistochemical analyses will be also performed in the 
tumor tissue and lymph nodes to study the modifications induced by the 
diet on lymph node populations and, in case, on tumor biology.
This “window of opportunity” study, which will be conducted in 
patients not receiving other medical treatments, will give the oppor-
tunity to test the effect of the FMD where used alone, i .e. without the 
confou nding effect o f o ther t reatments, s u ch a s chemotherapy,
Finally, to assess the clinical impact of NET-related inflammatory
features, Sangaletti and colleagues applied their signature to a cohort of
high-risk AML patients who had been treated with a combination of
chemotherapy (with citarabine) and immunomodulation (with lenali-
domide). According to the NET-related inflammatory signature, AML
cases could be subdivided into two groups, which differed significantly
from each other in OS. A similar result was obtained using a minimal
signature consisting of three genes belonging to the NET-related in-
flammatory signature. The relevance of NET, in NPM-1–driven myelo-
proliferation, was further demonstrated by immunizing NPM1-mutant
mice, which showed a worsened myeloproliferation and the presence of
myeloid cell blasts. In sum, their data indicate that stromal/ECM
changes, NETs, and BM inflammatory conditions can support genetic
events that move towards the development and progression of a mye-
loid malignancy.
5. Conclusions
Overall, the eighth annual conference of “Innovative therapies,
monoclonal antibodies, and beyond” provided a wide picture of recent
advances in the understanding of the role of the immune system in
cancer, the molecular mechanisms responsible for neoplastic transfor-
mation, the biology of cancer cells, and the immunological mechanisms
regulating tumor-host interaction. Key features emerged from the final
discussion mainly related to the mechanisms of tumor clonal evolution
as well as tumor escape and resistance from immuno-surveillance or
checkpoint inhibitors. The role of tumor heterogeneity, tumor micro-
environment, the gut microbiome, and the practice of using a fasting
mimicking diet (FMD) for tumor growth control were presented and
discussed. The possibility that tumor refractoriness in TNBC to im-
munotherapy regimens is potentially due to PD-L1–expressing CSC
compartment represents a yet-unexplored mechanism of therapy re-
sistance that opens the way to future intra-Institutional investigations.
Gaining an in-depth comprehension of biological, molecular, and im-
munological mechanisms currently represents a major challenge for all
clinicians and scientists involved in the debate, and represents the ne-
cessary future direction for modern cancer immunotherapy.
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